News und Analysen
2 Reasons Pfizer Is on Our Minds Today
In this Market Foolery podcast, and with the big news coming out of healthcare, host Chris Hill calls upon the expert insight of Industry Focus: Healthcare host Kristine Harjes.First, they....
Why Ardelyx Inc Skyrocketed Higher Today
Ardelyx (NASDAQ: ARDX) stock rose 44% on Thursday after the company announced positive data from the phase 3 T3MPO-2 trial testing its irritable bowel syndrome drug, tenapanor, after the close of....
Why AcelRx Pharmaceuticals Inc Got Cut in Half Today
AcelRx Pharmaceuticals (NASDAQ: ACRX) is down 57% at 12:41 p.m. EDT after the Food and Drug Administration rejected the company's pain medication Dsuvia. As I said earlier this month when the....
Carl Zeiss Meditec – Geht es jetzt auf neue Jahreshochs?
Die Aktie von Carl Zeiss Meditec ist im Jahr 2017 mit einem Kursplus von 30% bereits recht gut gelaufen. Das aktuelle Jahreshoch bei 47,78 Euro muss jedoch nicht das Ende der Fahnenstange....
Carl Zeiss Meditec – Geht es jetzt auf neue Jahreshochs?
Die Aktie von Carl Zeiss Meditec ist im Jahr 2017 mit einem Kursplus von 30% bereits recht gut gelaufen. Das aktuelle Jahreshoch bei 47,78 Euro muss jedoch nicht das Ende der Fahnenstange....
3 Signs Myriad Genetics' High-Growth Days Are Over
Myriad Genetics (NASDAQ: MYGN) used to be the creme de la creme of the genetic testing industry. It had healthy profit margins, a growing business, and was well-known among investors and health....
7 Essential Rules for Investing in Biotech Stocks
Successful investing boils down to minimizing risk while maximizing the potential for reward. That's true whether you're investing in stocks, bonds, cryptocurrencies, or anything else. But how you....
5 Game-Changing Cancer Drug Innovations Being Developed Right Now
Image source: Getty Images."The emperor of all maladies, the king of terrors." This phrase was used by a 19th century surgeon to describe cancer. More than a century later, the description....
5 Game-Changing Cancer Drug Innovations Being Developed Right Now
Image source: Getty Images."The emperor of all maladies, the king of terrors." This phrase was used by a 19th century surgeon to describe cancer. More than a century later, the description....
How Safe Is AbbVie's Dividend?
The pharmaceutical industry has been a favorite among dividend investors, and AbbVie (NYSE: ABBV) has put together an impressive track record of treating its shareholders well. Dating back to....
How Safe Is AbbVie's Dividend?
The pharmaceutical industry has been a favorite among dividend investors, and AbbVie (NYSE: ABBV) has put together an impressive track record of treating its shareholders well. Dating back to....
How Safe Is AbbVie's Dividend?
The pharmaceutical industry has been a favorite among dividend investors, and AbbVie (NYSE: ABBV) has put together an impressive track record of treating its shareholders well. Dating back to....
Can Johnson & Johnson Really Start Growing Again?
It's hard to satisfy investors -- even a strong performance can just lead us to want more. Case in point: Johnson & Johnson (NYSE: JNJ). Though the healthcare giant's stock has posted a solid....
Can Johnson & Johnson Really Start Growing Again?
It's hard to satisfy investors -- even a strong performance can just lead us to want more. Case in point: Johnson & Johnson (NYSE: JNJ). Though the healthcare giant's stock has posted a solid....
Why Snap, Seattle Genetics, and Pretium Resources Jumped Today
Wednesday was a generally good day for investors on Wall Street, featuring a gentle rise of about 0.15% to 0.25% for major benchmarks like the Dow and the S&P 500. The White House continued to....
Why Snap, Seattle Genetics, and Pretium Resources Jumped Today
Wednesday was a generally good day for investors on Wall Street, featuring a gentle rise of about 0.15% to 0.25% for major benchmarks like the Dow and the S&P 500. The White House continued to....
Is Pfizer the Best Dividend Stock in Healthcare?
Pfizer Inc.'s (NYSE: PFE) sales have fallen sharply since its top-selling Lipitor lost patent protection back in 2012. However, steps management has taken to control costs and invest in cancer....
Is Pfizer the Best Dividend Stock in Healthcare?
Pfizer Inc.'s (NYSE: PFE) sales have fallen sharply since its top-selling Lipitor lost patent protection back in 2012. However, steps management has taken to control costs and invest in cancer....
Is AbbVie the Best Dividend Stock in Healthcare?
AbbVie (NYSE: ABBV) is making headway toward diversifying itself away from its best-selling drug, Humira, but Humira still accounts for most of its sales and that makes buying AbbVie, because of....
Is AbbVie the Best Dividend Stock in Healthcare?
AbbVie (NYSE: ABBV) is making headway toward diversifying itself away from its best-selling drug, Humira, but Humira still accounts for most of its sales and that makes buying AbbVie, because of....
Is AbbVie the Best Dividend Stock in Healthcare?
AbbVie (NYSE: ABBV) is making headway toward diversifying itself away from its best-selling drug, Humira, but Humira still accounts for most of its sales and that makes buying AbbVie, because of....
Is Johnson & Johnson the Best Dividend Stock in Healthcare?
Johnson & Johnson (NYSE: JNJ) has increased the amount of money it returns to investors in the form of dividends every year for more than 50 years. Its diversification across various....
Is Johnson & Johnson the Best Dividend Stock in Healthcare?
Johnson & Johnson (NYSE: JNJ) has increased the amount of money it returns to investors in the form of dividends every year for more than 50 years. Its diversification across various....
BASTIDE : Exercice 2016-2017 : EBITDA : +16% - Résultat opérationnel courant : +15% - Résultat net impacté par des éléments non récurrents - 3 acquisitions en Respiratoire et Nutrition-Perfusion - Objectif de chiffre d'affaires 2017-2018 revu à l
Exercice 2016-2017 :
EBITDA : +16%
Résultat opérationnel courant : +15%
Résultat net impacté par des éléments non récurrents
3 acquisitions en Respiratoire et Nutrition-Perfusion
Objectif....
Here's Why Abeona Therapeutics Inc. Stock Spiked Today
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biotech developing novel gene therapies to treat rare genetic disorders, popped as much as 14% higher on Wednesday morning after....